A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors
Status:
Completed
Trial end date:
2017-05-02
Target enrollment:
Participant gender:
Summary
This open-label, multi-center study will evaluate the safety, tolerability, and
pharmacokinetics of RO5212054 [PLX3603] in participants with BRAF V600-mutated advanced solid
tumors. Cohorts of participants will receive escalating oral doses of RO5212054. Anticipated
time on study treatment is until disease progression or unacceptable toxicity occurs.